CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

4Plants/AzythromycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2329 Quinquina-Stevia/Azythromycin Wiki 1.00
drug1331 Hydroxychloroquine/Azithromycine Wiki 1.00

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D018746 Systemic Inflammatory Response Syndrome NIH 0.58
D009102 Multiple Organ Failure NIH 0.50
D058186 Acute Kidney Injury NIH 0.23
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.23

There is one clinical trial.

Clinical Trials

1 Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes

Our previous work on plants has indicated significant antimalarial and antiviral activities. Of these plants, two recipes are proposed for evaluation for COVID-19. It is Cinchona, an antimalarial and a combination of 4 plants with antiviral, antimalarial, antitussive and anti-inflammatory properties. The phase II clinical trial, with three arms and at a rate of 77 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non-inferiority test aimed at comparing the therapeutic impact in "add on" to Azithromycin, phytomedicines versus Hydroxychloroquine in asymptomatic COVID-19 patients. After 10 days of treatment, viral clearance and symptom progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied

NCT04501965 Covid19 Combination Product: Hydroxychloroquine/Azithromycine Combination Product: Quinquina-Stevia/Azythromycin Combination Product: 4Plants/Azythromycin

Primary Outcomes

Description: Virologic clearance from admission to discharge at days 3, 6 and 14

Measure: Virologic clearance of throat swabs or lower respiratory tract secretions

Time: day 3 to day 14

Secondary Outcomes

Description: number of patients who developed fever, cough, and any other clinical sign typical of the disease

Measure: COVID-19 symptoms development

Time: day 1 to day 14

Description: number of participants who developed treatment-related adverse effects

Measure: Adverse effects

Time: day 1 to day 14

Description: number of patients whose condition worsened on D14

Measure: Worsened condition

Time: day 1 to day 14

No related HPO nodes (Using clinical trials)